BioMarin Pharmaceutical (HAM:BM8) Cyclically Adjusted FCF per Share: €0.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €51.66
GF Value €76.14
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted FCF per Share?

BioMarin Pharmaceutical HAM:BM8 +0.54% 75 Cyclically Adjusted FCF per Share is €0.34 as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 75/100 and a GF Value™ of €76.14. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.874. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.34 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioMarin Pharmaceutical was 17.00% per year. The lowest was -15.00% per year. And the median was 2.85% per year.

As of today (2026-07-28), BioMarin Pharmaceutical's current stock price is €51.66. BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.34. BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is 151.94.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 129.53. And the median was 148.33.


BioMarin Pharmaceutical  (HAM:BM8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=51.66/0.34
=151.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 129.53. And the median was 148.33.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.43 -0.37 -0.36 -0.33 0.09

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.17 -0.04 0.09 0.34

HAM:BM8 vs TECH, CYTK, SMMT: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.


HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.874/330.2130*330.2130
=0.874

Current CPI (Mar. 2026) = 330.2130.

BioMarin Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.390 241.018 -0.534
201609 -0.194 241.428 -0.265
201612 -0.285 241.432 -0.390
201703 -0.810 243.801 -1.097
201706 -0.148 244.955 -0.200
201709 -0.020 246.819 -0.027
201712 -0.122 246.524 -0.163
201803 -0.335 249.554 -0.443
201806 -0.273 251.989 -0.358
201809 -0.013 252.439 -0.017
201812 0.036 251.233 0.047
201903 -0.424 254.202 -0.551
201906 -0.302 256.143 -0.389
201909 0.170 256.759 0.219
201912 -0.018 256.974 -0.023
202003 -0.286 258.115 -0.366
202006 -0.028 257.797 -0.036
202009 0.284 260.280 0.360
202012 -0.241 260.474 -0.306
202103 0.388 264.877 0.484
202106 0.253 271.696 0.307
202109 0.356 274.310 0.429
202112 -0.160 278.802 -0.190
202203 -0.355 287.504 -0.408
202206 0.142 296.311 0.158
202209 0.663 296.808 0.738
202212 -0.150 296.797 -0.167
202303 -0.474 301.836 -0.519
202306 0.224 305.109 0.242
202309 0.550 307.789 0.590
202312 -0.045 306.746 -0.048
202403 0.059 312.332 0.062
202406 0.449 314.175 0.472
202409 0.915 315.301 0.958
202412 0.802 315.605 0.839
202503 0.742 319.799 0.766
202506 0.739 322.561 0.757
202509 1.486 324.800 1.511
202512 0.243 324.054 0.248
202603 0.874 330.213 0.874

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.34 mean?
BioMarin Pharmaceutical (HAM:BM8) has a Cyclically Adjusted FCF per Share of €0.34 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is €0.34. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share compare to TECH and CYTK?
BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share of €0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is €0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Cyclically Adjusted FCF per Share of €0.34. The stock's GF Value™ is €76.14, compared to a current price of €51.66 — trading 32.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.34. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Cyclically Adjusted FCF per Share is €0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €51.66 is trading 32.2% below its estimated GF Value™ of €76.14.

Key valuation signals for HAM:BM8:

  • Cyclically Adjusted FCF per Share: €0.34
  • GF Value™: €76.14 vs. price of €51.66 (32.2% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.66
Price
€76.14
GF Value